Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma : Episode 13

Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

December 19, 2023

Ulka Vaishampayan, MD
Alan Tan, MD

News

Video

Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.

EP: 1.Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

EP: 2.Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

EP: 3.Imaging and Staging Considerations in Renal Cell Carcinoma

EP: 4.Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

EP: 5.Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

EP: 6.Comparing Treatment Combinations in Renal Cell Carcinoma

EP: 7.Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

EP: 8.Sequencing and Second-Line Therapy in RCC: Patient Scenario

EP: 9.Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

EP: 10.Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

EP: 11.Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

EP: 12.Triple Combination Therapies in RCC: Clinical Trial Insights

EP: 13.Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

Related Videos

Elias Jabbour, MD

Samer A. Srour, MB ChB, MS

Christina L. Roland, MD, MS, FACS

Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center

Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Michael Leung, PharmD, an expert on colorectal cancer

A panel of 4 experts on colorectal cancer

Samer A. Srour, MB ChB, MS

Samer A. Srour, MB ChB, MS

Related Content

Debu Tripathy, MD, professor, chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Vepdegestrant Shows Potential in ESR1-Mutant ER+/HER2– Breast Cancer

April 22nd 2024

Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

FDA Approval Insights: Ponatinib in Ph+ ALL

Jonathan T. Yang, MD

AZD1390 Demonstrates Initial Safety, May Enhance Radiotherapy Efficacy in Glioblastoma

John H. Strickler, MD, associate professor, medicine, member, the Duke Cancer Institute; Michael Leung, PharmD, BCOP, clinical pharmacy specialist, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center; Arvind N. Dasari, MD, MS, associate professor, the Department of GI Medical Oncology, the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Margot O’Neill, PA-C, MHS, physician assistant, oncology, the Duke Cancer Institute

CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

March 25th 2024

Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

Samer A. Srour, MB ChB, MS

CTX130 Provides Disease Control and Manageable Safety in Advanced ccRCC

Related Content

Debu Tripathy, MD, professor, chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Vepdegestrant Shows Potential in ESR1-Mutant ER+/HER2– Breast Cancer

April 22nd 2024

Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

FDA Approval Insights: Ponatinib in Ph+ ALL

Jonathan T. Yang, MD

AZD1390 Demonstrates Initial Safety, May Enhance Radiotherapy Efficacy in Glioblastoma

John H. Strickler, MD, associate professor, medicine, member, the Duke Cancer Institute; Michael Leung, PharmD, BCOP, clinical pharmacy specialist, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center; Arvind N. Dasari, MD, MS, associate professor, the Department of GI Medical Oncology, the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Margot O’Neill, PA-C, MHS, physician assistant, oncology, the Duke Cancer Institute

CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

March 25th 2024

Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

Samer A. Srour, MB ChB, MS

CTX130 Provides Disease Control and Manageable Safety in Advanced ccRCC

Latest Conference Coverage

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.